Pratt William D, Wang Danher, Nichols Donald K, Luo Min, Woraratanadharm Jan, Dye John M, Holman David H, Dong John Y
U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter St., Fort Detrick, MD 21702-5011, USA.
Clin Vaccine Immunol. 2010 Apr;17(4):572-81. doi: 10.1128/CVI.00467-09. Epub 2010 Feb 24.
Ebola viruses are highly pathogenic viruses that cause outbreaks of hemorrhagic fever in humans and other primates. To meet the need for a vaccine against the several types of Ebola viruses that cause human diseases, we developed a multivalent vaccine candidate (EBO7) that expresses the glycoproteins of Zaire ebolavirus (ZEBOV) and Sudan ebolavirus (SEBOV) in a single complex adenovirus-based vector (CAdVax). We evaluated our vaccine in nonhuman primates against the parenteral and aerosol routes of lethal challenge. EBO7 vaccine provided protection against both Ebola viruses by either route of infection. Significantly, protection against SEBOV given as an aerosol challenge, which has not previously been shown, could be achieved with a boosting vaccination. These results demonstrate the feasibility of creating a robust, multivalent Ebola virus vaccine that would be effective in the event of a natural virus outbreak or biological threat.
埃博拉病毒是高致病性病毒，可在人类和其他灵长类动物中引发出血热疫情。为满足针对几种导致人类疾病的埃博拉病毒的疫苗需求，我们研发了一种多价候选疫苗（EBO7），该疫苗在单一基于复杂腺病毒的载体（CAdVax）中表达扎伊尔埃博拉病毒（ZEBOV）和苏丹埃博拉病毒（SEBOV）的糖蛋白。我们在非人类灵长类动物中评估了我们的疫苗对致死性攻击的肠胃外和雾化途径的效果。EBO7疫苗通过任何一种感染途径都能为两种埃博拉病毒提供保护。值得注意的是，通过加强接种疫苗可以实现对雾化攻击的苏丹埃博拉病毒的保护，而此前尚未有此报道。这些结果证明了创建一种强大的多价埃博拉病毒疫苗的可行性，这种疫苗在自然病毒爆发或生物威胁情况下将是有效的。
